NetScientific PLC has announced its interim results for the six months ended 30 June 2023. The company reported total income of £1.15 million, a 64% increase compared to the same period last year. The majority of the income came from the core services provided by NetScientific and its subsidiary, EMV Capital. Group losses from operations decreased slightly to £1.6 million, with losses at subsidiary portfolio companies Glycotest and ProAxsis increasing due to further investments in their growth strategies. The portfolio valuation decreased to £35.5 million, mainly due to the decline in the PDS Biotechnology share price. However, there were improvements in the fair value of non-listed portfolio companies, including Vortex Biotech Holdings, DName-iT, and Q-Bot. The company's Capital Under Advisory increased to £26.1 million, providing potential future profit for the group. NetScientific also reported profitable partial exits from certain portfolio holdings, generating non-dilutive funding and underpinning valuations. The company's strategic focus includes value creation, external funding of portfolio companies, proactive portfolio management, increased fee generation, selective group divestments, and exploring new fund opportunities. NetScientific remains confident about the prospects of the group and its position in the deeptech and life sciences VC industry.